BTG licenses haemofiltration device patents to Fresenius Medical Care

BTG licenses haemofiltration device patents to Fresenius Medical Care

BTG licenses haemofiltration device patents to Fresenius Medical Care

BTG licenses haemofiltration device patents to Fresenius Medical Care

London, UK, 22 December 2006: BTG plc (LSE: BGC), the medical innovations company, today announces that it has granted Fresenius Medical Care AG & Co. KGaA a non-exclusive licence for the global rights to patents relating to a haemofiltration device for €4.5 million fully paid.

Developed by researchers at Cincinnati Children's Hospital, the device improves the treatment of acute renal failure by enabling automated adjustments to be made during a haemofiltration session, reducing the possibility of human error and the need for supervision.

Louise Makin, BTG's Chief Executive Officer, said: "We are pleased to have signed this agreement relating to the haemofiltration patents, and we are actively seeking additional licensees."

For further information contact:

BTG
Andy Burrows, Director of Investor Relations
+44 (0)20 7575 1741; mobile: +44 (0)7990 530605
Christine Soden, Chief Financial Officer
+44 (0)20 7575 1591

Financial Dynamics
Ben Atwell
+44 (0)20 7831 3113

About BTG

BTG in-licenses, develops and commercialises pharmaceuticals and other medical technologies. With a substantial and growing revenue stream of royalties and milestone payments from out-licensed products, BTG continues to strengthen its pipeline of preclinical and clinical development programmes. Active in the fields of oncology, diseases of ageing, neuroscience, drug repositioning and medical devices, BTG works from its offices in London, Philadelphia and Osaka with a global partner network of healthcare companies and research organisations. For further information, visit: www.btgplc.com.

Back to press releases